INSULET CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $PODD in the last 7 days.
No SEC Form 4 filings for $PODD in the last 30 days.
See all $PODD insider activity →Insulet Corporation (PODD) launched Omnipod Discover, a data platform for Omnipod 5 insulin pump users and healthcare providers. The platform offers personalized reports and has seen adoption by over 15,000 users and 1,800 healthcare professionals in the U.S. Insulet reported that 32% of users saw a 3% or more increase in time in range. The platform is also available in several other countries.
Jefferies reduced Insulet's (PODD) price target to $190 from $275, citing competition concerns. The stock is down 52% YTD. Q2 revenue was $801.7M, up 23.5% YoY, beating estimates. Multiple firms downgraded PODD due to attrition and competition fears, despite strong financials and a perfect Piotroski Score of 9.
Insulet (PODD) shares fell 2.3% to $132.96 amid a broader market decline, extending losses since its Q2 2026 earnings. The company lowered its full-year revenue outlook due to weaker Type 2 diabetes patient retention, despite beating estimates. Analysts have cut price targets, with the consensus now at $144. Two board directors also resigned, adding to investor concerns.
Recent PODD coverage spans earnings, corporate actions and financial news.
The platform could improve user engagement and clinical outcomes, supporting demand for Insulet's pump ecosystem.
Target cut suggests weaker outlook and may trigger sell pressure.
The stock is under pressure from lingering concerns over revenue outlook and governance changes.
The amendment reduces borrowing costs and expands liquidity, which should modestly improve the company's credit profile.
The plan may affect compensation expense and cash flow but has limited immediate price impact.
AlphAI scores every news story that mentions PODD with an AI model for sentiment and relevance, and aggregates insider trades from INSULET CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Insulet Corporation (PODD) launched Omnipod Discover, a data platform for Omnipod 5 insulin pump users and healthcare providers. The platform offers personalized reports and has seen adoption by over 15,000 users and 1,800 healthcare professionals in the U.S. Insulet reported that 32% of users saw a 3% or more increase in time in range. The platform is also available in several other countries.
2 min readJefferies reduced Insulet's (PODD) price target to $190 from $275, citing competition concerns. The stock is down 52% YTD. Q2 revenue was $801.7M, up 23.5% YoY, beating estimates. Multiple firms downgraded PODD due to attrition and competition fears, despite strong financials and a perfect Piotroski Score of 9.
2 min readInsulet (PODD) shares fell 2.3% to $132.96 amid a broader market decline, extending losses since its Q2 2026 earnings. The company lowered its full-year revenue outlook due to weaker Type 2 diabetes patient retention, despite beating estimates. Analysts have cut price targets, with the consensus now at $144. Two board directors also resigned, adding to investor concerns.
1 min readINSULET CORP (PODD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 21, 2026, Insulet Corporation (the “ Company ”) entered into the Ninth Amendment to Credit Agreement (the “ Amendment ”) with the lenders and other parties thereto and Morgan Stanley Senior Funding, Inc., as admin
1 min readINSULET CORP (PODD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Adoption of Nonqualified Deferred Compensation Plan On September 14, 2026, the Talent and Compensation Committee (the "Comm
1 min readResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.
3 min readINSULET CORP (PODD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 3, 2026, Timothy J. Scannell, a member of the Board of Directors (the "Board") of Insulet Corporation (the "Co
1 min readInsulet PODD reports strong growth in Omnipod 5 AID system adoption, with Q2 2026 revenues up 23.8%. The company faces competition and macroeconomic pressures but has raised international growth guidance. PODD's earnings beat estimates for four straight quarters, with a 22.2% long-term growth rate. Management expects continued expansion and product development, including Omnipod 6 and a Type 2 system launch in 2027.
3 min readInsulet (PODD) reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next quarter's guidance. Peers iRhythm (IRTC), ResMed (RMD), and DexCom (DXCM) also reported earnings, with mixed market reactions. PODD is down 11.6% since reporting, while DXCM is up 20.6%.
3 min readiRhythm (IRTC) reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates. ResMed (RMD) reported $1.46B in revenue, up 8.6% YoY, in line with expectations. Insulet (PODD) reported $801.7M in revenue, up 23.5% YoY, beating estimates but missing guidance. IRTC stock is down 4.4%, RMD up 3.4%, and PODD down 11.6% since reporting.
2 min read
